Efficient Treatment Strategies for Neurological and Kidney Diseases using the Power of Artificial Intelligence and Systems Biology.

We study the interactions between the host and oral/gut microbiome through the integration of multi-omics data and employ this information to identify effective drug targets and prognostic biomarkers. We also perform drug repositioning applications to use the existing drugs for treatment of such diseases and identify their potential side effects.

Our Current Programs

CandidateIndicationPreclinicalPhase 1Phase 2Phase 3NDA FiledMarket
BASH-001Chronic Kidney Disease
BASH-002Kidney Cancer
BASH-003Alzheimer's Disease
BASH-004Parkinson's Disease

Our Current Platforms

PlatformUnder DevelopmentAlphaBetaProductionPublication
The Human Gut Microbiome Atlas
Drug Repositioning Platform

Latest News

View All News

November 11, 2021

Bash Biotech Releases a report about the GutMicroNet: an interactive platform for gut microbiome interaction exploration

June 11, 2021

Bash Biotech Releases a report about the stratification of patients with clear cell renal cell carcinoma to facilitate drug repositioning

View Details

April 13, 2021

Bash Biotech Releases a report about the iNetModels 2.0: an interactive visualization and database of multi-omics data

View Details

April 1, 2021

Bash Biotech Releases a report about the Global and temporal state of the human gut microbiome in health and disease

View Details

January 14, 2021

Bash Biotech Releases Preliminary Report of iNetModels 2.0: An Interactive Visualization and Database of Multi-omics Data

View Details

July 21, 2020

Bash Biotech raises $1M In Seed Funding To Bring The Power of Artificial Intelligence Into Biopharmaceutical Industry

View Details